$SGYP..$7.10 in pre-mkt...Synergy CEO says 'all options are open' following Phase 3 data
After Synergy Pharmaceuticals (SGYP) announced top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses in adult patients with chronic idiopathic constipation, Synergy CEO Gary Jacobs reportedly told Bloomberg in a phone interview that 'all options are open at this point" as the company seeks to maximize the value of the asset. Jacobs added that newly reported data topped expectations, especially on tolerability, and that the company has 'high confidence' that its second phase 3 trial data will be positive as well. In March, Bloomberg reported that Synergy was talking to advisers about a potential sale of the company after its competitor, Salix Pharmaceuticals, had agreed to be acquired by Valeant Pharmaceuticals (VRX). In pre-market trading, Synergy shares rose $2.46, or 53%, to $7.10.
Sheff's Station...All Aboard...Sign Up Here!
